



## **CERTIFICATE OF MAILING**

Typed or Printed name of person signing this certificate:

Wendy A. Frick

Signed: Wendy a Frick

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re a	pplication of: Lang	) Examiner: F	Helms, Larry Ronald	
Serial No.: 09/674,035		Art Unit: 1642		
Filed:	December 11, 2000	) )		
For:	DETECTING THE EXPRESSION OF THE DESC1 GENE IN SQUAMOUS	Attorney Docket	Attorney Docket No.: 22727/04078	

U.S. Patent and Trademark Office Box Sequence P.O. Box 2327 Arlington, Virginia 22202 JUL 3 2002 TECH CENTER 1600/2900

## STATEMENT REGARDING SEQUENCE LISTING

Dear Sir:

In response to the Communication from the Examiner mailed on May 30, 2002, (a copy of which is attached hereto), Applicant submits herewith a paper copy of a Sequence Listing as required by 37 C.F.R. 1.821(c), and a copy of the same Sequence Listing in computer readable form as required by 37 C.F.R. 1.821(e). The content of the paper copy and the computer readable copy of the Sequence Listing are the same.

As noted by the Examiner, the Sequence Listing mailed to the Patent Office contained a few typographical errors. Specifically, nucleotides 328 and 330 in SEQ ID NO. 1 were not the same as the nucleotides shown in Figure 1A. Nucleotide 1172 in SEQ ID NO. 3 was not the same as shown in Figure 1 B and, and amino acids 121 and 391 in SEQ ID NO. 4 were not the same as shown in Figure 1 B. With respect to amino acid 104 in SEQ ID NO. 2, Applicants

were unable to find any inconsistency with Figure 1 A. With respect to nucleotides 553 and 555 in SEQ ID NO. 1, Applicants also were unable to find any inconsistency with Figure 1 A. If the Examiner disagrees, he is encouraged to call the undersigned at the number listed below. The sequences in the Sequence Listing are the same as the sequences in the text and the figures of the application as filed. Accordingly, the Sequence Listing adds no new matter.

Applicants respectfully request entry of the Sequence Listing into the case.

Respectfully submitted,

Dated: 911 25,200

Pamela A. Docherty, Reg. No. 40

(216) 622-8416

JUN 2 8 2002 22

Application No. \_\_\_\_\_

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1.	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.		
	2.	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).		
	3.	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).		
	4.	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."		
		The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).		
	6	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).		
П	7	. Other:		
LJ.	٠,	TECH CENTER 1600/290		
Applicant Must Provide:				
区	Α	n initial or substitute computer readable form (CRF) copy of the "Sequence Listing".		
Ø		In initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its ntry into the specification.		
X	а	statement that the content of the paper and computer readable copies are the same and, where pplicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).		
Fo	r (	questions regarding compliance to these requirements, please contact:		
		Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212		

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

For Patentin software help, call (703) 308-6856